MiNDERA Corporation

What MiNDERA Corporation does

Mindera Health (legal entity MiNDERA Corporation) is a US-based precision medicine company commercializing Mind.Px, a molecular diagnostic that prospectively predicts individual patient response to biologic drug classes (TNF-alpha, IL-17, IL-23 inhibitors) used to treat moderate-to-severe plaque psoriasis. The proprietary Dermal Intelligence platform combines a minimally invasive, penny-sized dermal biomarker patch that extracts RNA transcripts from skin in roughly five minutes with next-generation sequencing and machine-learning classifiers trained on transcriptomic data from purpose-built clinical cohorts (242-patient STAMP, 205-patient randomized MATCH utility study). Reporting a >91% positive predictive value, 14-day turnaround, and demonstrated annual cost-savings range of $5,138 to $13,141 per patient when clinicians follow the test result, Mind.Px is positioned as a tool to replace the trial-and-error prescribing cycle behind the ~52% average biologic response rate.

The company operates a CAP-accredited, CLIA-certified, ISO 13485:2016-certified diagnostic laboratory in Vista, California, where specimens submitted via test requisition forms from dermatology practices are processed. Revenue is generated almost entirely through laboratory diagnostic testing services billed to insurance payers, Medicare/Medi-Cal, self-funded employers, PBM partners (WellDyne, Liviniti), and government contracts including a 5-year GSA award serving the VA/DOD system and Medi-Cal provider credentialling. The commercial model is enterprise field sales led by a dedicated sales function (VP of Sales, Managed Markets VP, Chief Commercial Officer) layered with network-provider and channel agreements (MultiPlan, Contigo Health, MediNcrease, Occum Health) and employer/payer coverage collaborations (Highmark coverage-with-evidence project). As of the April 2026 SEC Form D filing the company disclosed no revenue, indicating the business remains in pre-revenue commercial buildout despite product availability.

Name

MiNDERA Corporation

Legal name

Mindera Corporation

Website

https://minderahealth.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Mindera Health is a US precision medicine company that commercializes Mind.Px, a dermal biomarker patch-based molecular test predicting biologic drug response in moderate-to-severe plaque psoriasis patients, serving dermatologists, payers, PBMs, and government health programs.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF)

akta.pro secondary industries

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Molecular diagnostic testing
• Dermal biomarker patch
• Precision medicine diagnostics
• Psoriasis biologic prediction
• RNA transcriptomic analysis

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Laboratory Diagnostic Testing Services: Mind.Px precision medicine test performed in company's CAP accredited, CLIA certified facility in Vista, CA. Test results delivered to ordering physicians within 14 days. Revenue generated through laboratory testing services billed to insurance payers, Medicare/Medi-Cal, and self-funded employers.
2. Payer/Reimbursement Contracts: Revenue from contracted relationships with insurance companies, pharmacy benefit managers, and provider networks. Includes coverage with evidence projects, network provider agreements, and government contracts (GSA, VA/DOD facilities, Medi-Cal).

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Mindera Health provides Mind.Px, a laboratory-developed molecular diagnostic test that uses a proprietary dermal biomarker patch to extract RNA from psoriatic skin lesions, then applies next-generation sequencing and machine-learning classifiers to prospectively predict individual patient response to biologic drug classes (TNFα, IL-17, IL-23 inhibitors). The test is performed in the company's CAP-accredited, CLIA-certified, ISO 13485:2016-certified laboratory in Vista, California, with reports delivered to ordering physicians within 14 days and reimbursed via insurance, Medicare/Medicaid, and self-funded employer channels.

Product overview

Mindera Health operates as a precision medicine company offering a unified platform approach to digital skin analytics. The flagship product is Mind.Px™, a predictive diagnostic test for psoriasis biologic therapy selection, powered by the Dermal Intelligence™ Platform which uses a proprietary dermal biomarker patch for RNA extraction and machine learning analysis. Supporting products include SkinAtlas™ (the molecular data repository) and Subtilitas (a translational research platform). The company commercializes Mind.Px directly to healthcare providers and payers, with financial assistance programs like Mindera Assist available for patients.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• >91% positive predictive value in predicting biologic drug response
• +5 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Eleven partnerships are on record, tiered flagship and core.

• Mountaineer BiosciencesflagshipStrategic or Co-development Partner · 18 March 2026Launched Subtilitas precision translational medicine platform for dermatology and immunology. Integrates Mindera Health's non-invasive skin transcriptomics and data science tools with Mountaineer Biosciences' translational and clinical expertise. Platform enables objective, biology-driven insights for patient stratification, biomarker discovery, and clinical development. Available for partnership with biopharmaceutical companies, academic investigators, and CROs.
• MultiPlancoreChannel Partner/ Reseller/ Distributor · 16 December 2024Network provider agreement for Mindera's Vista, CA laboratory. Mind.Px available to PHCS and MultiPlan Networks health plan members. MultiPlan delivers value to more than 700 healthcare payors, over 100,000 employers, 60 million consumers, and 1.4 million contracted providers.
• National Psoriasis FoundationcoreGTM or Marketing Partner · 19 November 2024Strategic partnership to improve psoriasis patient outcomes and raise awareness of precision medicine. NPF serves more than 4 million people annually with resources, tools, and information. Partnership supports NPF Care Path and helps patients and doctors make more efficient and accurate treatment decisions.
• Medi-CalcoreChannel Partner/ Reseller/ Distributor · 19 August 2024Medi-Cal provider credentialling enables Mind.Px access for over 15 million Medi-Cal beneficiaries in California. State Medicaid program serves one in three Californians including nearly four in ten children, one in five nonelderly adults, and two million seniors and people with disabilities.
• Liviniti (formerly Southern Scripts)coreChannel Partner/ Reseller/ Distributor · 29 February 2024Innovative Pharmacy Benefit Manager partnership for psoriasis patient management pilot program. Liviniti serves self-funded employers with pass-through pricing and transparent business model. Collaboration utilizes Mind.Px to improve clinical outcomes while reducing biologic drug costs.
• Occum HealthcoreChannel Partner/ Reseller/ Distributor · 6 November 2023Commercial agreement making Mind.Px available to Occum Health's more than 500 self-insured clients and key strategic partners. Healthcare solutions company focused on delivering savings and improved benefits to self-insured employers.
• Contigo Health ConfigureNetcoreChannel Partner/ Reseller/ Distributor · 23 October 2023Provider network contract making Mind.Px available to Contigo Health ConfigureNet clients and their health plan members. Contigo Health is a health benefits platform leading direct-to-employer and direct-to-provider relationships with nationwide provider access.
• General Services Administration (GSA)coreChannel Partner/ Reseller/ Distributor · 10 October 20235-year GSA contract enabling access to Mind.Px for over 9.6 million veterans, active duty, retirees and their families served by VA Health System and Department of Defense Medical Treatment Facilities.
• MediNcrease Health PlanscoreChannel Partner/ Reseller/ Distributor · 3 October 2023National provider network contract making Mind.Px available to more than 15 million lives served by MediNcrease clients and payers. National provider network and provider advocacy firm servicing commercial health, workers' compensation, and auto medical markets.
• Highmark Inc.coreChannel Partner/ Reseller/ Distributor · 10 April 2023Coverage with evidence project evaluating Mind.Px's impact on physician prescribing behavior and net savings for Pennsylvania, West Virginia and Delaware health plans. CEO of Diversified Businesses Deborah L. Rice-Johnson serves on Mindera Health Board.
• WellDynecoreChannel Partner/ Reseller/ Distributor · 4 January 2022Definitive agreement with innovative PBM to improve management of moderate-to-severe psoriasis patients. WellDyne has partnered with more than 2,000 clients managing more than 3 million plan members. Partnership leverages Mind.Px for specialty drug optimization.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• DermTech: Commercial-stage molecular dermatology diagnostics company using non-invasive skin sampling (tape stripping) to detect genomic markers for skin cancer and inflammatory skin conditions. Direct peer to Mindera given shared approach of non-invasive dermal sampling + RNA/molecular analysis for dermatology therapeutic decision-making.
• Castle Biosciences: Molecular diagnostics company with dermatology-focused tests (e.g., DecisionDx-Melanoma, DecisionDx-SCC) that use genomic profiling to guide treatment decisions. Highly relevant peer because of dermatology focus, specialty-Dx business model, and CLIA/CAP certified laboratory operations.
• Exagen: Specialty diagnostics company focused on autoimmune and rheumatic diseases (SLE, RA) with proprietary blood-based biomarker tests used to guide therapy selection. Highly comparable given the CEO overlap (Ron Rocca led Exagen), autoimmune/dermatology adjacency, and precision-medicine payer business model.

Broad incumbents

• Veracyte: Established specialty molecular diagnostics company offering RNA-based genomic tests across oncology and other specialties. Comparable business model of CLIA/CAP-certified specialty lab, payer coverage build-out, and AI/ML-driven decision-support tests for therapy selection.
• Guardant Health: Liquid-biopsy molecular diagnostics company with NGS-based tests for oncology therapy selection and monitoring. Comparable as a multiomic, NGS + ML-driven specialty Dx selling to providers and payers with significant reimbursement and coverage-with-evidence focus.
• Exact Sciences: Large molecular diagnostics company (Cologuard, Oncotype DX, TheraPrint) with extensive payer infrastructure and lab operations. Comparable as a specialty Dx scaling via evidence-based payer coverage and primary/secondary care provider ordering workflows.
• NeoGenomics: Oncology-focused clinical laboratory and molecular diagnostics services company with CLIA-certified labs and broad payer contracts. Comparable as a multiomic specialty Dx with similar cost-of-goods economics and oncology/therapy-selection positioning.
• Natera: Molecular diagnostics company with cell-free DNA and RNA-based specialty tests (oncology, transplant, women's health). Comparable as a multiomic specialty Dx with established payer coverage strategy and recurring test revenue model.

Emerging players

• Tempus AI: AI-powered precision medicine company combining molecular profiling and clinical data for therapy selection and clinical trial enrollment. Comparable because of AI/ML biomarker analytics, pharma/CRO research services, and predictive test positioning.
• SkylineDx: Molecular diagnostics company developing biomarker-based tests for therapy selection, primarily in oncology and inflammatory diseases. Comparable as a translational biomarker Dx that validates transcriptomic signatures to inform therapeutic choice via lab-developed tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MinderaHealth
• YouTubeyoutube.com/@MinderaHealth
• Facebookfacebook.com/people/Mindera-Health/100076469641529
• LinkedInlinkedin.com/company/mindera-diagnostics

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiNDERA Corporation